Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coca-Cola/FUZE

This article was originally published in The Tan Sheet

Executive Summary

Castanea Partners has completed the sale of FUZE Beverage to the Coca-Cola company, the private equity firm announces March 21. Coca-Cola said in February it would purchase the brand, including products such as Slenderize, which contains chromium for energy and SuperCitrimax to suppress appetite (1"The Tan Sheet" Feb. 26, 2007, In Brief)...

You may also be interested in...



Food claim warning letter

Labeling for several FUZE Healthy Infuzions beverages stating vitamin B3 is "known to ... reduce cholesterol levels in blood" and polyphenols are "associated with reduced risk of developing cardiovascular disease and certain cancers" violates the Food, Drug & Cosmetic Act, FDA says in a recent 1warning letter to FUZE Beverages. These claims "promote [the] products for use as drugs." Additionally, the products "are labeled with a dietary supplement disclaimer statement," the agency adds. "Because these products are conventional foods, not dietary supplements, their labels should not include this disclaimer." The dietary supplement industry voiced its concerns to FDA at a recent meeting and asked that dietary supplements and functional foods be given a level "regulatory playing field" (2"The Tan Sheet" Dec. 11, 2006, p. 3). Coca-Cola announced Feb. 1 it intends to purchase FUZE to expand its beverage portfolio...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel